Key Takeaways
- LTR Pharma has signed its first US commercial agreement for ROXUS with Shed Holdings LLC, focusing on telehealth commercialization.
- The agreement stipulates a target of 150,000 prescription units within the first year, contingent upon final agreements and supply readiness.
- The structure includes a two-year exclusivity in the US telehealth market, dependent on performance requirements.
New Commercial Agreement for ROXUS
LTR Pharma (ASX:LTP) has announced a significant step in its US market strategy by entering a binding commercial agreement with Shed Holdings LLC for its erectile dysfunction medication, ROXUS. This deal focuses on leveraging the Mavrox telehealth platform for direct-to-consumer sales. While the agreement marks a shift from strategic intentions to actionable steps, it remains contingent on final agreements being reached within 60 days and readiness for product launch.
The ROXUS initiative is part of LTR’s broader erectile dysfunction program, which utilizes intranasal vardenafil. The dual-track strategy includes SPONTAN, which is pursuing the FDA 505(b)(2) pathway, while ROXUS aims for a quicker market presence through personalized medicine. Today’s announcement is the first formal disclosure of a commercial framework specifically for ROXUS.
In this arrangement, Shed Holdings is tasked with patient acquisition and telehealth logistics, while LTR retains ownership of the product and its related intellectual property. The telehealth agreement established today is a key component of fulfilling ROXUS’s market entry.
The company has indicated that successful rollout hinges on establishing relationships with designated US 503A pharmacies, which are vital for product fulfillment and supply chain operations. Previous indications of market validation were noted in Australia, where LTR reported over 1,000 prescriptions issued under the TGA Special Access Scheme. Partnerships with Aptar Pharma, Mayne Pharma, and EBOS/Symbion have been established to enhance LTR’s commercial manufacturing and distribution capacity.
The commercial terms include a target of 150,000 prescription units in the first year following commercialization, although this target is not guaranteed and depends on supply and execution of definitive agreements. Additionally, LTR will enjoy two-year exclusivity in the US direct-to-consumer telehealth channel, given that performance requirements are met. If the performance conditions are not satisfied, LTR may downgrade the agreement to non-exclusive status.
Key aspects to monitor include whether LTR and Shed Holdings can finalize definitive agreements within the stipulated time and whether they can meet launch readiness criteria, as supply chain coordination plays a critical role in reaching the outlined targets. The company has reported $24.1 million in cash, indicating sufficient funding for short-term goals. However, rising losses underline the importance of meeting milestones promptly.
Overall, LTR’s binding agreement with Shed Holdings is a constructive move towards commercializing ROXUS in the US, but its success will depend on finalizing agreements and navigating the product launch process effectively.
The content above is a summary. For more details, see the source article.